Amplia Therapeutics’ Promising Study on Narmafotinib for Pancreatic Cancer

Amplia Therapeutics Ltd. ((INNMF)) announced an update on their ongoing clinical study.

Amplia Therapeutics Ltd. is conducting a study titled ‘A Phase 1b/2a, Multicenter, Open Label Study of the Safety, Efficacy and Pharmacokinetics of Narmafotinib in Combination With Modified FOLFIRINOX in Pancreatic Cancer Patients.’ The study aims to evaluate the safety and effectiveness of narmafotinib, a focal adhesion kinase (FAK) inhibitor, when used with the chemotherapy regimen FOLFIRINOX in patients with metastatic pancreatic cancer. This research is significant as it explores potential new treatment options for a challenging cancer type.

The intervention being tested is narmafotinib, administered as oral capsules daily. It is combined with the mFOLFIRINOX chemotherapy regimen, which is given on Day 1 and Day 15 of each 28-day cycle. The goal is to find an optimal dose of narmafotinib that can be used in future studies.

The study is designed as an interventional trial with a non-randomized, sequential model. It consists of two parts: Part A involves dose-escalation to determine safe dose levels, while Part B compares two selected doses for efficacy. The study is open-label, meaning no masking is used, and its primary purpose is treatment.

Key dates for the study include its start on April 29, 2025, and the last update on August 26, 2025. These dates are crucial for tracking the study’s progress and ensuring timely updates for stakeholders.

This clinical study update could influence Amplia Therapeutics’ stock performance positively, as successful results may enhance investor confidence and interest. The study’s progress is also relevant in the context of the competitive landscape of pancreatic cancer treatments, where new, effective therapies are highly sought after.

The study is ongoing, with further details available on the ClinicalTrials portal.